These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


241 related items for PubMed ID: 16835986

  • 1. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
    Lin HY, Lin SP, Chuang CK, Wraith JE.
    J Chin Med Assoc; 2006 May; 69(5):228-32. PubMed ID: 16835986
    [Abstract] [Full Text] [Related]

  • 2. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC, Chien YH, Lai MY, Hwu WL.
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [Abstract] [Full Text] [Related]

  • 3. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 4. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 5. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 6. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.
    Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
    [Abstract] [Full Text] [Related]

  • 7. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Sep; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 8. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 9. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 10. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
    Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, Pers YM, Baron C, Belmatoug N.
    Orphanet J Rare Dis; 2015 May 13; 10():62. PubMed ID: 25968608
    [Abstract] [Full Text] [Related]

  • 11. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 13; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 12. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):66-72. PubMed ID: 21112800
    [Abstract] [Full Text] [Related]

  • 13. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A.
    Am J Hematol; 2013 Mar 15; 88(3):179-84. PubMed ID: 23400823
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 15; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 15. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Cappellini MD, Carubbi F, Di Rocco M, Giona F, Giuffrida G.
    Blood Cells Mol Dis; 2023 Jan 15; 98():102705. PubMed ID: 36327675
    [Abstract] [Full Text] [Related]

  • 16. Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1.
    Cerón-Rodríguez M, Barajas-Colón E, Ramírez-Devars L, Gutiérrez-Camacho C, Salgado-Loza JL.
    Mol Genet Genomic Med; 2018 Jan 15; 6(1):27-34. PubMed ID: 29471591
    [Abstract] [Full Text] [Related]

  • 17. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 15; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 18. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A.
    Blood Cells Mol Dis; 2014 Dec 15; 53(4):253-60. PubMed ID: 24950666
    [Abstract] [Full Text] [Related]

  • 19. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study.
    Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, Kaplan P, Mankin H, Xavier R, Angell J, Fitzpatrick MA, Rosenthal D.
    Clin Genet; 2008 May 15; 73(5):430-40. PubMed ID: 18312448
    [Abstract] [Full Text] [Related]

  • 20. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
    Deegan P, Khan A, Camelo JS, Batista JL, Weinreb N.
    Orphanet J Rare Dis; 2021 Feb 18; 16(1):92. PubMed ID: 33602299
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.